Time: Mondays 16:00 hrs / 04.00 PM CET
Location: Zoom
Contact: Prof Dr Ruud Delwel, h.delwel@erasmusmc.nl, Mrs. Tessa Mannee, t.mannee@erasmusmc.nl
Duration: 1 hour
Cost: Free of charge & no registration required
Webinar ID: 941 4638 9345
Zoom link: https://zoom.us/j/94146389345
06 September 2021
Alexander van Oudenaarden, Hubrecht Institute, Utrecht, The Netherlands
Ribosomal profiling in single cells
|
13 September 2021
Len Zon, Boston Children’s Hospital, Boston, U.S.A.
Stem cell clonality and the niche
|
20 September 2021
Ravi Majeti, Stanford University, Stanford, U.S.A.
Stem cells in human AML
|
27 September 2021
Elli Papaemmaniul, Memorial Sloan Kettering Cancer Center, New York, U.S.A.
Genomic studies of myeloid disease
|
04 October 2021
Jorge di Paola, Washington University School of Medicine, Saint Louis, U.S.A.
Molecular mechanisms of ETV6 associated thrombocytopenia and cancer predispositione
|
11 October 2021
Nicoletta Sorvillo, University of Bern, Bern, Switzerland
NETs and extracellular citrullination: friends or foes in vascular health?
|
18 October 2021
Christopher Ott, Massachusetts General Hospital, Boston, U.S.A.
Chemical modulation of enhancers
|
25 October 2021
Marina Cavazzana, Necker Hospital, Paris, France
Gene therapy in genetic disorders
|
01 November 2021
John Welch, Washington University School of Medicine, Saint Louis, U.S.A.
Decitabine responses in AML/MDS
|
08 November 2021
Dave Bodine, National Human Genome Research Institute, Bethesda, U.S.A.
A practical and theoretical understanding of Diamond Blackfan anemia revealed by genomics
|
15 November 2021
Marjorie Brand, Ottawa Hospital Research Institute, Ottawa, Canada
Cell fate decisions in hematopoiesis and T-cell leukemogenesis
|
22 November 2021
Walter Kahr, The Hospital for Sick Children & University of Toronto, Toronto, Canada
Insights into megakaryocyte development from inherited platelet disorders
|
29 November 2021
Scott Armstrong, Dana-Farber Cancer Institute, Boston, U.S.A.
Targeting epigenetic mechanisms in leukemia
|
06 December 2021
Amanda Fisher, MRC London Institute of Medical Sciences & Imperial College London, London, U.K.
Epigenetic memory
|
20 December 2021
Madhav Dhodapkar, Emory University, Atlanta, U.S.A.
Early tumor immune interactions and opportunities for prevention in plasma cell malignancies
|
Grant Department Hematology ErasmusMC for single cell analyses in hematologic malignancies
The Hematology department has received a grant of €100.000 from the Stichting Leukemie (www.leukemie.nl) for single cell analysis of hematological malignancies, in particular acute myeloid leukemia (AML).
AML is an example of a heterogeneous group of hematologic malignancies with a variable response to therapy. The heterogeneity of AML is illustrated by the different (combinations of) mutations that occur with AML. Based on these mutations the prognosis of the AML patient can be estimated. However, despite the fact that prognostics in AML has greatly improved in recent decades, there is still much to be learned.
Residual disease during therapy of a haematological malignancy is a good predictor for getting recurrence of disease. We have recently demonstrated that the use of next generation sequencing in residual disease detection greatly improves the quantitative prediction of a recurrence (M. Jongen et al., NEJM 378, 2018).
The analyses in the above study were performed on the bulk of the AML cells. Analysis of DNA abnormalities at the level of a single cell will ultimately be necessary to determine which cells within a heterogeneous population of cells are critically important for the return of the AML. The grant from the Stichting Leukemie will be used to purchase equipment for the analysis of residual disease in AML at the single cell level.
